The fourth Subject was safely treated with the low-dose of BB-301 in December 2024, and the fifth Subject was safely treated with the low-dose of BB-301 in early February 2025. The sixth Subject is ...

Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...

The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...

Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dys ...

A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.

In a digital world, Gen Z and Alpha go analogue, taking to slow communication with inland letters, postcards and other creative missives ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

The University of Rochester will confront significant blows to groundbreaking clinical studies, UR says in a legal challenge to cuts in NIH funding.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They ...

A 6-year-old boy was apparently well 4 months prior reporting to the clinic, when his parents noticed an asymptomatic, progressive change in the texture of his fingernails and toenails. They ...